2Saggiorato E, Cappia S, De Giuli P, et al. Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. J Clin Endocrinol Metab, 2001,86:5152-5158.
3Cvejic D, Savin S, Golubovic S, et al. Galectin-3 and carcinoembryonic antigen expression in medullary thyroid carcinoma:possible relation to tumor progression. Histopathology, 2000,37:530-535.
4Herrman ME, LiVolsi VA, Pasha TL, et al. Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. Arch Pathol Lab Med, 2002,126:710-713.
二级参考文献11
1Kawachi K, MatsushitaY,Yonezawa S,et al. Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. Hum Pathol,2000,31: 428-433.
2Cvejic D,Savin S, Golubovic S,et al.Galectin-3 and carcinoembryonic antigen expression in medullary thyroid carcinoma: possible relation to tumour progression. Histopathology, 2000, 37: 530-535.
3Beesley MF, Mclaren KM. Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules.Histopathology,2002,41:236-243.
4RenshawAA,Gould EW. Why there is the tendency to ''overdiangnose'' the follicular variant of papillary thyroid carcinoma. Am J Clin Pathol, 2002,117:19-21.
5Miettinen M,Kovatich AJ,Karkkainen P. Keratin subsets in papillary and follicular thyroid lesions:A paraffin section analysis with diagnosis implications.Vichows Arch,1997,431:407-413.
6Baloch ZW,Abraham S,Roberts S,et al. Differential expression of cytokeratins in follicular variant papillary carcinoma:an imunohistochemical study and its diagnostic utility. Hum Pathol,1999,30:1166-1171.
7Inohara H,Honjo Y,Yoshii T,et al. Expression of galectin-3 in fine-needle aspirates as a marker differentiating benign from malginant thyroid neoplasms. Cancer,1999,85:2475-2481.
8Coli A,Bigotti G,Zucchetti F,et al.Galectin-3,a marker of well-differentiated thyroid carcinoma,is expressed in thyroid nodules with cytological atypia.Histopathology,2002,40:80-87.
9van Hoeven KH, Kovatich AJ, Miettinen M. Immunocytochemical evaluation of HBME-1, CA 19-9, and CD-15 (Leu-M1) in fine-needle aspirates of thyroid nodules. Diagn Cytopathol, 1998,18: 93-97 .
10Hirokawa M, Horiguchi H,Wakatsuki S,et al.Intranodal benign thyroid tissue: significance of HBME-1 in differentiation from metastatic papillary thyroid carcinoma. APMIS,2001,109: 875-880.
6Fukunaga M, Shinozaki N, Endo Y, et al.Atypical adenoma of the thyroid.A clinico-pathologic and flow cytometric DNA study in comparison with other follicular neoplasma [J].Acta Pathol Jpn, 1992,42(9):632-8.
7Mai K T, Yazdi H M, Perkins D G, et al.Papillary thyroid carcinoma and related thyroid neoplastic lesions:a light microscopic study with emphasis on nuclear changes[J].Tumori, 2000,86(2):238-49.
8Mai K T, Landry D C, Thomas J, et al.Follicular adenoma with papillary architecture: a lesion mimicking papillary thyroid carcinoma [J].Histopathology, 2001,39(1):25-32.
9Livolsi V A, Mazzaferri E L, Schneider A B, et al.World Health Organization classification of tumors, pathology and genetics of tumors of endocrine organs[M].Lyon: LARC Press, 2004:57-66.
10Hedingen C E, Williams E D, Soloin L H.Histological typing of thyroid tumors[M].2nd ed.Berlin: Spring-Veriag, 1988:113.
